Trial Profile
A study to evaluate the humoral response against different peptides in multiple sclerosis patients treated with Natalizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 07 Nov 2016 New trial record